However, in cancers with BRCA1/2 mutations, homologous recombination is impaired, forcing cells to depend on less accurate and alternative DNA repair mechanisms, such as PARP-mediated repair, which makes them particularly susceptible to PARP inhibition [33]. Here, PARP1 is linked to cancer.